Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Povidone-Iodine | 2 | 2020 | 213 | 1.32 | Why? |
| Meningitis, Fungal | 1 | 2021 | 17 | 0.93 | Why? |
| Nose Diseases | 1 | 2021 | 139 | 0.78 | Why? |
| Orbital Diseases | 1 | 2021 | 339 | 0.65 | Why? |
| Opportunistic Infections | 1 | 2021 | 602 | 0.56 | Why? |
| Anti-Infective Agents, Local | 1 | 2020 | 520 | 0.51 | Why? |
| Eye Infections, Viral | 1 | 2020 | 517 | 0.48 | Why? |
| Mucormycosis | 1 | 2021 | 832 | 0.45 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.30 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.29 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.22 | Why? |
| Povidone | 1 | 2020 | 21 | 0.22 | Why? |
| Hydroxybutyrates | 1 | 2021 | 162 | 0.22 | Why? |
| Antiviral Agents | 8 | 2021 | 41703 | 0.21 | Why? |
| Crotonates | 1 | 2021 | 141 | 0.21 | Why? |
| Administration, Ophthalmic | 1 | 2020 | 53 | 0.21 | Why? |
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2021 | 106 | 0.21 | Why? |
| Toluidines | 1 | 2021 | 145 | 0.21 | Why? |
| Ophthalmic Solutions | 1 | 2020 | 136 | 0.20 | Why? |
| Medicine, Ayurvedic | 1 | 2021 | 155 | 0.20 | Why? |
| Folic Acid | 1 | 2021 | 172 | 0.19 | Why? |
| Placebos | 1 | 2021 | 629 | 0.17 | Why? |
| Retinoblastoma | 1 | 2017 | 41 | 0.17 | Why? |
| SARS Virus | 2 | 2020 | 13021 | 0.17 | Why? |
| Plant Preparations | 1 | 2021 | 276 | 0.17 | Why? |
| Retinal Neoplasms | 1 | 2017 | 45 | 0.17 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.16 | Why? |
| Cell Culture Techniques | 1 | 2021 | 704 | 0.16 | Why? |
| Nitriles | 1 | 2021 | 1053 | 0.15 | Why? |
| Coronavirus Infections | 8 | 2021 | 253789 | 0.14 | Why? |
| Plants, Medicinal | 1 | 2021 | 622 | 0.14 | Why? |
| Steroids | 1 | 2020 | 904 | 0.14 | Why? |
| Protein Interaction Domains and Motifs | 1 | 2020 | 2134 | 0.12 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.12 | Why? |
| Drug Design | 2 | 2020 | 2627 | 0.11 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.11 | Why? |
| Antifungal Agents | 1 | 2021 | 1828 | 0.10 | Why? |
| Enzyme Inhibitors | 1 | 2021 | 1881 | 0.10 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.10 | Why? |
| Drug Discovery | 2 | 2021 | 3092 | 0.10 | Why? |
| Pyrazines | 1 | 2020 | 1783 | 0.10 | Why? |
| Amides | 1 | 2020 | 1864 | 0.09 | Why? |
| Drug Evaluation, Preclinical | 1 | 2020 | 3347 | 0.09 | Why? |
| Biomarkers, Tumor | 1 | 2017 | 1314 | 0.09 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.08 | Why? |
| Host-Pathogen Interactions | 3 | 2021 | 11041 | 0.08 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.07 | Why? |
| Humans | 19 | 2021 | 930598 | 0.06 | Why? |
| Nervous System Diseases | 1 | 2021 | 4092 | 0.06 | Why? |
| Treatment Outcome | 4 | 2021 | 51732 | 0.06 | Why? |
| Hyperhomocysteinemia | 1 | 2021 | 24 | 0.06 | Why? |
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2021 | 37 | 0.06 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.05 | Why? |
| Nitric Oxide Synthase Type III | 1 | 2021 | 87 | 0.05 | Why? |
| Mutation | 1 | 2021 | 12376 | 0.05 | Why? |
| Computer-Aided Design | 1 | 2021 | 94 | 0.05 | Why? |
| Biomedical Research | 1 | 2021 | 5270 | 0.05 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.05 | Why? |
| Databases, Pharmaceutical | 1 | 2020 | 345 | 0.04 | Why? |
| Drug Repositioning | 3 | 2021 | 5683 | 0.04 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.04 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2021 | 12361 | 0.04 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.04 | Why? |
| Diffusion of Innovation | 1 | 2021 | 440 | 0.04 | Why? |
| Molecular Epidemiology | 1 | 2021 | 1638 | 0.04 | Why? |
| Catalytic Domain | 1 | 2021 | 1757 | 0.03 | Why? |
| India | 2 | 2021 | 11875 | 0.03 | Why? |
| Risk Factors | 1 | 2021 | 71621 | 0.03 | Why? |
| Hypertension, Pulmonary | 1 | 2021 | 970 | 0.03 | Why? |
| Clinical Trials as Topic | 2 | 2021 | 7330 | 0.03 | Why? |
| Molecular Targeted Therapy | 1 | 2020 | 1579 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.02 | Why? |
| Immunohistochemistry | 1 | 2017 | 2275 | 0.02 | Why? |
| Cells, Cultured | 1 | 2021 | 5835 | 0.02 | Why? |
| Dexamethasone | 1 | 2020 | 2055 | 0.02 | Why? |
| Genotype | 1 | 2021 | 4697 | 0.02 | Why? |
| Molecular Dynamics Simulation | 1 | 2020 | 4155 | 0.02 | Why? |
| Animals | 3 | 2021 | 78931 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Models, Molecular | 1 | 2020 | 7616 | 0.02 | Why? |
| Artificial Intelligence | 1 | 2021 | 3543 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2021 | 9537 | 0.02 | Why? |
| Computer Simulation | 1 | 2020 | 4982 | 0.02 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.02 | Why? |
| Research Design | 1 | 2021 | 5830 | 0.02 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Adult | 1 | 2021 | 244371 | 0.02 | Why? |
| Models, Theoretical | 1 | 2021 | 6659 | 0.01 | Why? |
| Viral Load | 1 | 2020 | 15850 | 0.01 | Why? |
| Prevalence | 1 | 2021 | 25773 | 0.01 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.01 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 8843 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Child | 1 | 2017 | 70012 | 0.01 | Why? |
Bhattacharyya's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(98)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(70)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_